NCT06152731

HRD Tests for Ovarian cancER

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 88 (estimated)
• Sponsor: Centre Francois Baclesse · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study concerns patients with Invasive epithelial ovarian cancer, primary Fallopian tube carcinoma, ovarian-type peritoneal carcinoma, and with an indication of a first-line platinum-based chemotherapy. To determine HRD status, 2 separate tests will be performed in the study: 1. Giscar assay : developed by the sponsor 2. myChoice assay If one or two tests identifies a HRD status : a PARP inhibitor treatment may be initiated according to current recommendations

Conditions

• Ovarian Cancer

Interventions

Type	Name	Description
GENETIC	tests to determine HRD status	Test Giscar AND test myChoice will be performed. If one or two tests identifies a HRD status : a PARP inhibitor treatment may be initiated according to current recommendations

Timeline

• Start date: 2024-02-15
• Primary completion: 2031-06-01
• Completion: 2031-06-01
• First posted: 2023-12-01
• Last updated: 2025-09-17

Locations

4 sites across 1 country: France